...
首页> 外文期刊>Transfusion: The Journal of the American Association of Blood Banks >Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands.
【24h】

Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands.

机译:筛选除抗D以外的红细胞抗体以检测胎儿和新生儿的溶血性疾病的效果:荷兰的一项人口研究。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Hemolytic disease of the fetus and newborn (HDFN) is a severe disease, resulting from maternal red cell (RBC) alloantibodies directed against fetal RBCs. The effect of a first-trimester antibody screening program on the timely detection of HDFN caused by antibodies other than anti-D was evaluated. STUDY DESIGN AND METHODS: Nationwide, all women (1,002 in 305,000 consecutive pregnancies during 18 months) with alloantibodies other than anti-D, detected by a first-trimester antibody screen, were included in a prospective index-cohort study. In a parallel-coverage validation study, patients with HDFN caused by antibodies other than anti-D, that were missed by the screening program, were retrospectively identified. RESULTS: The prevalence of positive antibody screens at first-trimester screening was 1,232 in 100,000; the prevalence of alloantibodies other than anti-D was 328 in 100,000, of which 191 of 100,000 implied a risk for occurrence of HDFN because the father carried the antigen. Overall,severe HDFN, requiring intrauterine or postnatal (exchange) transfusions, occurred in 3.7 percent of fetuses at risk: for anti-K in 11.6 percent; anti-c in 8.5 percent; anti-E in 1.1 percent; Rh antibodies other than anti-c, anti-D, or anti-E in 3.8 percent; and for antibodies other than Rh antibodies or anti-K, in none of the fetuses at risk. All affected children, where antibodies were detected, were promptly treated and healthy at the age of 1 year. The coverage validation study showed a sensitivity of the screening program of 75 percent. Five of 8 missed cases were caused by anti-c, with delay-induced permanent damage in at least 1. CONCLUSION: First-trimester screening enables timely treatment of HDFN caused by antibodies other than anti-D, however, with a sensitivity of only 75 percent. A second screening at Week 30 of c- women will enhance the screening program. Severe HDFN, caused by antibodies other than anti-D, is associated with anti-K, anti-c, and to a lesser extent with other Rh-alloantibodies.
机译:背景:胎儿和新生儿的溶血性疾病(HDFN)是一种严重的疾病,是由针对胎儿RBC的母体红细胞(RBC)同种抗体引起的。评估了早孕抗体筛查程序对及时检测由非D抗体引起的HDFN的影响。研究设计和方法:在全国范围内,前期妊娠筛查研究纳入了所有妇女(在孕前三个月连续305,000例怀孕中有1,002例)通过抗孕D抗体筛查发现了抗D以外的同种抗体。在一项平行覆盖验证研究中,回顾性鉴定了筛查程序遗漏的由抗-D抗体以外的抗体引起的HDFN患者。结果:孕早期筛查阳性抗体的患病率为每100,000例中有1,232例。抗D抗体以外的同种抗体的患病率为100,000人中有328人,其中100,000人中有191人隐含发生HDFN的风险,因为父亲携带该抗原。总体上,需要宫内或产后(交易所)输血的重度HDFN发生率在3.7%的高危胎儿中:11.6%的人接受抗K;抗C率为8.5%;抗E占1.1%; 3.8%的抗c,抗D或抗E抗体除外的Rh抗体;对于Rh抗体或抗K抗体以外的其他抗体,没有一个胎儿处于危险之中。所有受影响的儿童,只要检测到抗体,都将在1岁时得到及时治疗并保持健康。覆盖范围验证研究显示筛选程序的敏感性为75%。 8例漏诊病例中有5例是由抗c引起的,至少由延迟引起的永久性损害。结论:孕早期筛查可以及时治疗由非D抗体引起的HDFN,但敏感性仅为75%。在30周内对c型女性进行第二次筛查将增强筛查程序。由抗D抗体以外的抗体引起的严重HDFN与抗K,抗c相关,在较小程度上与其他Rh-allo抗体相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号